Rhythm Pharmaceuticals Appoints Yann Mazabraud as Executive Vice President, Head of International

Read more from the original source:
Rhythm Pharmaceuticals Appoints Yann Mazabraud as Executive Vice President, Head of International

Private placement of existing shares and major shareholder announcement

Company announcement no. 32 - 20 14 September 2020

See the article here:
Private placement of existing shares and major shareholder announcement

PLx Pharma Inc. to Present Virtually at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

SPARTA, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products, VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as “VAZALORE”™), announced today that Natasha Giordano, President and Chief Executive Officer, and Rita O’Connor, Chief Financial Officer, will present virtually at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit as follows:

The rest is here:
PLx Pharma Inc. to Present Virtually at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Novan Provides Pipeline and Priority Development Programs Update

- Lead product candidate, SB206 currently being evaluated in B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum with topline data targeted for Q2 2021 -

Excerpt from:
Novan Provides Pipeline and Priority Development Programs Update

NextCure Announces Appointment of John G. Houston, Ph.D., to its Board of Directors

BELTSVILLE, Md., Sept. 14, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of John G. Houston, Ph.D., to its board of directors as of September 10, 2020. Dr. Houston has more than 30 years of experience in the pharmaceutical and biotech industry and currently serves as president and chief executive officer of Arvinas, Inc. In addition, Judith Li has announced that she is stepping down from the company’s board of directors.

Go here to see the original:
NextCure Announces Appointment of John G. Houston, Ph.D., to its Board of Directors

Voyager Therapeutics Appoints Michelle Quinn Smith as Chief Human Resources Officer

CAMBRIDGE, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the appointment of Michelle Quinn Smith as Chief Human Resources Officer. Ms. Smith brings over 30 years of experience in human resources to Voyager, including leadership roles at Flagship Pioneering, Takeda Pharmaceuticals, Genzyme, and Sanofi.

See original here:
Voyager Therapeutics Appoints Michelle Quinn Smith as Chief Human Resources Officer

Biosenta Announces Royalty License Agreement for North American Distribution

TORONTO, Sept. 14, 2020 (GLOBE NEWSWIRE) --  Biosenta Inc. ("Biosenta" or the "Company") listed on the CSE (CSE:ZRO) is pleased to announce - A strategic licensing partnership with Kleen Bee Labs was finalized today. This license will give the rights for distribution of DualXtiv, a broad-spectrum anti-microbial disinfectant, to club level, mass grocery, and retail chains across North America.

See more here:
Biosenta Announces Royalty License Agreement for North American Distribution

Notification of Managers’ transactions

Company announcement no. 33 - 20 14 September 2020

Go here to see the original:
Notification of Managers’ transactions

ERYTECH Announces the Hosting of a KOL Event as the TRYbeCA-1 Phase 3 Trial in Second-line Pancreatic Cancer Nears Complete Enrollment

LYON, France and CAMBRIDGE, Mass., Sept. 14, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announces the hosting of a Key Opinion Leader (KOL) Event to discuss the medical need in pancreatic cancer and the potential role of eryaspase in this setting.

Read more here:
ERYTECH Announces the Hosting of a KOL Event as the TRYbeCA-1 Phase 3 Trial in Second-line Pancreatic Cancer Nears Complete Enrollment

Cronos Group Inc. to Present at the CIBC 19th Annual Eastern Institutional Investor Conference

TORONTO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Executive Chairman, will speak at the CIBC 19th Annual Eastern Institutional Investor Conference on Thursday, September 17, 2020 at 2:40 p.m. EDT.

Link:
Cronos Group Inc. to Present at the CIBC 19th Annual Eastern Institutional Investor Conference